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MAJOR FEATURES OF HERPESVIRUSES
Herpesviruses are often associated with different 
human diseases. One of the common features of all the 
members of the human herpesvirus (HHV) family is their 
ability to establish life-long persistence in the host after 
the primary infection. The latent infection by the human 
gamma (γ) herpesviruses, Epstein — Barr virus (EBV) and 
Kaposi’s sarcoma virus (HHV8), could be established in 
lymphoid tissues. EBV, which was first identified in 1964, 
is a lymphotropic virus that infects more than 90% of the 
human population, and targets B cells for infection. 
The primary infection may be asymptomatic and 
often occurs in early childhood. When the infection 
occurs later on in life, EBV causes infectious mono-
nucleosis (IM). In immunosuppressed hosts, such 
as transplant recipients and AIDS patients, EBV may 
cause post-transplant lymphoproliferative disease 
(PTLD). EBV is also associated with several malignan-
cies, such as Burkitt’s lymphoma (BL), nasopharyngeal 
carcinoma (NPC), and Hodgkin’s lymphoma (HL). 
It is considered that the virus enters the host by 
infecting B cells, which infiltrate the epithelium of the 
oropharynx. After infection, the viral latent proteins 
are produced and the B cells turn into large immuno-
blasts that express six EBV-encoded nuclear antigens 
(EBNAs), three latent membrane proteins (LMPs) and 
two small non-polyadenylated RNAs (EBERs). Such 
cells may be targeted by cytotoxic T lymphocytes (CTLs) 
reacting with the latency associated viral antigens. 
The activated cells differentiate into antibody 
producing cells, and migrate to the oropharyngeal 
mucosa. In some of them lytic gene expression is 
activated and new virus particles are produced. The 
virus is usually shed through the saliva of the infected 
host. The EBV-infected memory B cell pool may be 
enriched by re-entry of the latently infected cells into 
the germinal centers, where clonal expansion takes 
place (reviewed in [1, 2]). 
INFECTION OF B CELLS WITH EBV IN VITRO
Infection of human B cells in vitro induces meta-
bolic activation, morphological transformation, cell 
proliferation and eventual immortalization. 
In EBV immortalized immunoblastic lines of non-
neoplastic origin (lymphoblastoid cell lines; LCLs) nine 
viral proteins are expressed. Similar patterns of EBNAs 
and LMPs expression take place in tonsil and blood B 
cells of IM patients and in the lymphoblasts of individuals 
with PTLD [3–5]. EBV is the most efficient transforming 
tumor virus in vitro (reviewed in [6]). Six of the eleven 
EBV-encoded gene products (EBNA-1, -2, -3, -5, -6, 
LMP-1) are essential for EBV-mediated transforma-
tion [7]. The latency III genes hijack the normal B cell 
growth pathways by activating of the constitutive growth 
promotion and external survival signals.
EBV encodes EBNA-2 that activates and regulates 
the transcription of Notch and PU.1 responsive promo-
ters of the cellular genes, such as c-myc, c-fgr, CD21 
and CD23 promoters. EBNA-2 binding to RBP-Jκ results 
in the constitutive expression of c-myc in LCLs ([8], for 
review see [9]), leading to change in cell phenotype, 
adhesion and activation molecules expression. LMP1 
activates TNFα/CD40 downstream signaling pathways 
that can stimulate cell growth and survival through acti-
vation of NFκB, jun and p38 MAPK (reviewed in [1]).
An aim of the present paper was to discuss the 
putative functions of the nuclear receptors that were 
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found to be differently expressed in the naïve and 
EBV-transformed B lymphocytes (see current issue, 
Yenamandra et al. [10]). 
NUCLEAR RECEPTOR PROFILING
As it was demonstrated in [10], only 17 genes 
showed consistent differences in expression — de-
crease in B cells, upregulation in EBV-infected cells 
and LCLs, or vice versa. The expression of 5 genes was 
elevated in EBV-transformed cells; whereas 12 genes 
were downregulated in LCLs [10].
Nuclear receptors that were up-regulated 
in the EBV-transformed cells
Nr2F2. Nuclear receptor subfamily 2, group F, 
member 2. This receptor is also known as a tran-
scriptional factor COUP2, or COUPTFII (NP_066285, 
OMIM *107773, gene is located on chromosome 
15q26.1-26.2, protein consists of 414 amino acids). 
The literature data concerning this receptor is quite 
poor. However, it may play an important role in EBV 
induced transformation, because COUPTFII is involved 
in the repression of Notch signaling. It can also down-
regulate the Apolipoprotein 1 [11, 12] (Fig. 1, a). 
Nr4A3. Nuclear receptor subfamily 4, group A, 
member 3. This protein is also called the Mitogen-
induced orphan receptor, MINOR (NP_775290, 
OMIM +600542, gene is located on chromosome 
9q22, protein is 626 amino acids long). It belongs to 
NUR77 fami ly proteins. It was shown that LPS, cy-
tokines, oxidized lipids, and low-density lipoproteins 
induced Nr4A1-3 in macrophages (reviewed in [13]). 
Overexpression of this protein may lead to the apop-
tosis of T cells. At certain conditions, MINOR supports 
the survival of cells (reviewed in [14, 15]) (Fig. 1, b). 
Nr4A3 can play an important role in the inflammatory 
signaling, because Nr4A receptors 1–3 are induced by 
inflammation (by NF-κB, for example) (see Fig. 1, b). 
Nr6A1. Nuclear receptor subfamily 6, group 
A, member 6. This receptor has few alternative 
names — Germ cell nuclear factor (GCNF), and 
Retinoid receptor-related testis associated receptor 
(RTR) (NP_201591, OMIM *602778, gene is locali-
zed to chromosome 9q33-34.1, protein consists 
of 480 amino acids). It is quite well studied protein 
(reviewed in [16]). Recently, it was shown that loss of 
Nr6A1 expression led to induction of Nanog, Oct4, 
Sox2, Stella and FGF4 expression upon retinoic acid 
(RA) treatment [17]. The other genes, such as Fgf8, 
Wnt1, Pax2/5, En1/2, and Gbx2, were downregulated 
in case of Nr6A1 expression loss [18]. An intriguing 
feature of this orphan receptor is ability to recruit DNA 
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Fig. 1. a — Properties of cluster of Nr2F proteins. Nr2F2 down regulates Apoliprotein 1 and Notch signaling. The up-regulated recep-
tors are shown is the red font; the down-regulated receptors are shown in blue. Sign “T” indicates inhibition of a process or a protein; 
stars — binding between proteins; text in green is related to EBV-field. b — Properties of cluster of NUR77 family proteins. NUR77 binds 
to RelA, bcl-2 and can induce apoptosis. EBNA-2 binds to NUR77 and blocks apoptosis. c — Properties of Nr641, PPARG and RARA 
nuclear receptors. Nr6A1 might be involved in the regulation of Notch signaling; PPARG can block NBκB pathway; RARA binds to Z 
promoter of EBV and can prevent the lytic cycle. d — Properties of RXR proteins. These proteins bind to Z promoter of EBV and prevent 
the induction of the lytic cycle. The up-regulated receptors are shown is the red font; the down-regulated receptors are shown in blue. 
e — Properties of estrogen receptors: the cross talk between ER pathway and Aryl hydrocarbon (dioxin) receptor (AhR) pathway
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methyltransferase (Dnmt3) to the Oct3/4 promoter, 
which resulted in silencing by hypermethylation [19] 
(Fig. 1, c).
RARA. Retinoic acid receptor α (NP_000955, 
OMIM *180240, gene is located on chromosome 
17q21.1, protein consists of 462 amino acids) is very 
well studied receptor (reviewed in [20]). It binds to 
DNA as a homodimer with the Retinoid X receptors 
(RXRs). It was shown that activated RARA can block 
growth of LCLs due to G0/G1 arrest, while activity of 
CDK2, -4, and -6 was inhibited, as well as cyclin A, 
D2 and D3 [21]. 
On the other hand, it was reported that EBV lytic 
cycle activation was inhibited upon RA treatment due 
to the direct binding between RARA and the EBV-en-
coded lytic protein BZLF1 [22, 23]. 
Earlier it was also found that retinoids inhibited 
naïve B cell proliferation, but promoted cell survival 
[24]. It is worth to mention that the promoter region of 
RARA contains estrogen receptor response element 
(see Fig. 1, c) [25].
RXRA. Retinoid X receptor α (NP_002948, OMIM 
*180245, gene is located on chromosome 9q34.3, 
protein consists of 462 amino acids). A ligand-bound 
receptor can activate transcription as a homodimer or 
heterodimer (with RARs, LXR, FXR, PPARG) from re-
sponsive elements containing two degenerate copies 
of the consensus motif AGGTCA. The same sites are 
used by RARs, THRs, VDR and RXRs (Fig. 1, d). 
It was shown (as for RARA), that RXRA could bind 
to the BZLF1 (Z-protein) and inhibit EBV lytic cycle 
[26, 27]. 
It was reported that RXR agonist treatment led to 
an activation of Bcl2a1 (BFL1) and, thus, decreased 
apoptosis in the naïve T-cells [26]. Moreover, recently 
it was found that EBNA-2 transactivated BFL1 through 
RBP-Jκ [27]. BFL1 was activated by CD40, TNF, IL-1, 
and NFκB as well.
Nuclear receptors that were down-regulated 
in the EBV-transformed cells
PPAR-γ. Peroxisome proliferator-activated re-
ceptor γ, also known as PPARG (NP_619725, OMIM 
*601487, gene is located on chromosome 3p21, protein 
consists of 475 amino acids) forms dimer with RXRs to 
activate transcription. It was shown that PPARG might 
function as a promoter-specific repressor of NF-κB 
target genes that regulate immunity and homeostasis 
[28]. PPARG binds to Rel A [29]. Decrease in PPAR-γ 
abolishes the nuclear export of RelA.
It was already shown that lymphocytes expressed 
functioning PPARG, and its activation led to apoptosis, 
or growth arrest [30, 31], or differentiation [32]. Inte-
restingly, the activation of PPARG in B cells by CD40 
ligand protects spleen B cells and B cell lymphomas 
tumor cells from apoptosis [33]. 
Another attractive feature of PPARG is the ability to 
bind pRb and histone deacetylase 3 (HDAC3) [34]. By 
binding to HDAC3, PPARG can induce cell cycle arrest 
of pRb positive cells in G1 phase. 
PPARG, as we mentioned above, can have both 
transactivating and transrepressing activity [35]. 
PPARG can repress some IFN-γ and LPS-inducible 
genes, such as IL-12 and IP10 (see Fig. 1, c). In their 
turn, cytokines can repress the activity of PPARG by 
inhibiting DNA binding [36].
ER-α. Estrogen receptor α, ESR (NP_000116, 
OMIM *133430, gene is located on chromosome 
6q25.1, 595 amino acids in the protein sequence). 
It was shown that promoter methylation decreased 
the level of ESR expression in colorectal tumors [37]. 
Recently, it was demonstrated that Arnt/AhR heterodi-
mer could bind to ESR1 (both, α and β). This multi-
protein complex (in the presence of p300) activates 
transcription from ER responsive elements (ERRE) 
[38] (Fig. 1, e). 
It was shown that ER-α and -β are expressed in 
peripheral blood B cells. B cells express more ER-β 
than ER-α [39]. However, only ER-α is needed to up-
regulate immunoglobulin production. Both activated 
forms are required for complete downregulation of 
lymphopoiesis in the bone marrow of mice [40, 41].
ER-β receptor is known also as ER2, ESR2 
(Q92731, OMIM *601663, gene is localized to chro-
mosome 14q, protein consists of 447 amino acids). 
ER-β putative DNA-binding domain shows 96% identity 
to that of ER-α, but the ligand-binding domain has 
much lower homology — only 56%. Actually, binding 
of ER-α to DNA and transcription of the ER-α depen-
dent genes are studied very well, but ER-β function 
is poorly known. It was published recently that ER-β 
was associated with mitochondria [42]. Interestingly, 
that treatment of mice by ER-α selective agonist led to 
the decrease in number of mature B cells, and to the 
enhancement of INF-γ production and IL-6 suppres-
sion [43]. The most intriguing fact is that a disruption 
of ER-β in mice led to myeloproliferative disease that 
resembled chronic myeloid leukemia with lymphoid 
blast crisis [44] (see Fig. 1, e).
Nr1H3. Nuclear receptor subfamily 1, group H, 
member 3, also known as Liver X receptor α (LXRA) 
(NP_005684, OMIM *602423, gene is localized to 
chromosome 11p12, protein consists of 447 amino 
acids). This protein binds to RXRs and to DNA as hete-
romider [45]. LXRs play important role in the lipid me-
tabolism and transport. It was shown that LXR ligands 
could inhibit expression of the inflammatory regulators, 
such, as INOS, COX-2, and IL6 in response to bacterial 
infection or LPS stimulation [46]. Moreover, LXRs-null 
mice are highly susceptible to infection with Listeria 
monocytogenes [47] (see Fig. 1, c).
Nr2F1. Nuclear receptor subfamily 2, group F, 
member 1, also known as transcription factor COUP1 
(TFCOUP1) (NP_005645, OMIM *132890, gene is 
located on chromosome 5q14, protein consists of 423 
amino acids). It was shown that Nr2F1 recognizes DNA 
consensus sites that are also sites for RARA, RXRs, 
VDR, and THR. The receptor shows high homology to 
v-ErbA protein. Interestingly that compared with naïve 
B-cells, BLs, and LCLs, transcription factor Nr2F1 
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was up-regulated in Reed/Sternberg cells of HL [48]. 
Unfortunately, there are only few studies devoted to 
Nr2F1 (see Fig. 1, a).
Nr3C1. Nuclear receptor subfamily 3, group C, 
member 1. This receptor is known as glucocorticoid 
receptor (GCCR) (NP_001018087, OMIM +138040, 
gene is localized to chromosome 5q31, protein con-
sists of 777 amino acids). About two decades ago 
it was shown that GCCR might enhance the B cell 
maturation and immunoglobulin production [49, 50]. 
An attempt to measure the concentration and activity of 
receptor in peripheral blood B cells and EBV-infected 
B cells was carried out [51]. However, no difference 
in the GCCR activity was observed. It was shown later 
on, that LPS-treated B cells are more resistant to the 
apoptosis, mediated by activated GCCR [52]. 
Interestingly, the activated GCCR induced CD40 
mRNA [53] and could inhibit growth arrest due to RA 
treatment [54]. The promoter of GCCR is down regu-
lated by PU.1 [55]. 
It was shown recently that endogenous glucocor-
ticoids are required for transcriptional suppression of 
INF-γ [56]. At the same time, activated GCCR acts as 
a co-activator for STAT5-dependent transcription [57] 
(see Fig. 1, c).
Nr4A1. Nuclear receptor subfamily 4, group A, 
member 1, homologues of mouse NUR77 (NP_775180, 
OMIM *139139, gene is localized to chromosome 
12q13, protein consists of 598 amino acids). It was 
shown that this receptor was induced rapidly and 
transiently by growth-stimulating agents in human 
lymphocytes [58]. LPS treatment of macrophages 
led to N4A1 induction by NF-κB [59]. In contrast to 
transcriptionally active nuclear localization [60], Nr4A1 
receptor exhibits its mitogenic effect through the target 
gene regulation. Its pro-apoptotic effect is realized in 
cytoplasm through regulation of mitochondrial activi-
ty [61]. It was found later that the orphan receptor is 
bound to Bcl-2 and could convert it to killer [62]. 
It should be mentioned that at different conditions 
and cell background NUR77 could be both induced 
and repressed by TNF-α and NF-κB [60, 63, 64]. 
NUR77 was implicated in B cell apoptosis [65], and 
EBNA-2 (but not LMP1) could protect B cells from 
NUR77-induced apoptosis [66, 67] (see Fig. 1, b).
RORC. RAR-related orphan receptor γ (RORG) 
(NP_005051, OMIM *602943, gene is located on 
chromosome 1q21, protein contains 518 amino acids). 
Importance of RORC was shown in experiments on 
the homozygous null mice — they lacked peripheral 
and mesenteric lymphnodes and Peyer patches [68, 
69]. Another interesting feature of such mice is loss of 
thymic expression of the anti-apoptotic factor Bcl-xL 
[68, 70] (see Fig. 1, c).
RXRB. Retinoid X receptor β (NP_068811, OMIM 
*180246, gene is localized to chromosome 6p21.3, 
protein consists of 533 amino acids). This receptor acts 
as transcription activator in the heterodimer with RARs, 
VDR, THR, LXR, and Farnesoid X receptor (FXR). 
RXRB increases their DNA binding and transacti-
vating ability of RARs, VDR, and THR [71, 72]. RXRB 
promoter is down-regulated by TNF-α and this repres-
sion is mediated by p38 MAP kinase, independently 
from NF-κB [73]. RXRB binds to Z protein as RXRA 
does [22, 23] and this binding inhibits the EBV lytic 
cycle (see Fig. 1, d).
THRB. Thyroid hormone receptor β (NP_000452, 
OMIM +190160, gene is located on chromosome 3p24.3, 
protein consists of 461 amino acids). This receptor was 
known before as ERBA-2, or human homologue of ret-
roviral ERBA protein (avian erytroblastic leukemia viral 
oncogene). Interestingly, homozygous knock-out mice 
had an elevated level of thyroid-stimulating hormone 
[74, 75]. However, the responsible genes for THRB 
remain largely unknown (see Fig. 1, c).
VDR. Vitamin D3 receptor (NP_000367, OMIM 
*601769, gene is localized to chromosome 12q12-14, 
protein consists of 427 amino acids). VDR possesses 
Zn-finger in its N-terminal domain. This part of protein 
binds to general transcription factor II B (TFIIB) [76]. 
It was shown quite long ago that the VDR-depen-
dent gene regulation is blocked in B cells (peripheral 
blood cells and LCLs) [77]. The active VDR pathway 
could inhibit proliferation and enhance differentiation 
of leukemic cells [78]. The level of VDR expression (at 
mRNA and protein levels) was lower in the EBV trans-
formed cells compared to tonsil B cells [78]. 
Recently an anti-tumor effect was proposed for vita-
min D and VDR (for review see [79, 80]) (see Fig. 1, c).
CLUSTERS OF NUCLEAR RECEPTORS 
We have analyzed the targeted nuclear receptors, 
and grouped them into clusters. A phylogram is pre-
sented on Fig. 2.
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Fig. 2. Phylogram of 16 nuclear receptors that expressed 
 differently in naïve and EBV-infected B-cells
Cluster of Nr2F proteins (COUP transcription 
factors). These two proteins are the most closely relat-
ed among all of the discussed receptors. The alignment 
score is 87 (Clustal W). Nr2F1 is downregulated but 
Nr2F2 is upregulated. Unfortunately, not much is known 
about these receptors. It is only known that Nr2F2 is 
involved in Notch signaling repression (see Fig. 1, a). It 
is important to continue the study on Nr2F2 receptor, 
because Notch pathway is used by EBV upon latency 
establishing: EBNA-2 and EBNA-3 family proteins regu-
late the expression of Notch-dependent genes.
Cluster of RXR proteins. These two receptors 
have alignment score of 69, it is just little lower than for 
THR and v-ERBA-77 (see the phylogenetic tree, Fig. 2). 
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The most interesting their feature is the ability to bind 
Z-protein of EBV and inhibit its transcriptional activity, 
i.e. prevent reactivation of the lytic cycle (see Fig. 1, d). 
That makes RXR proteins the important players in the 
control on latency. 
Cluster of NUR 77 family proteins. These proteins 
showed quite high alignment score — 47. Interestingly, 
NF-κB activates NOR1 and can both downregulate and 
upregulate NUR77 transcription (see Fig. 1, b). It was 
shown earlier that both receptors can regulate apop-
tosis. However, the cell fate depends on the delicate 
balance between them. EBNA-2 binds to NUR77, and 
this binding blocks apoptosis [66, 67]. 
Cluster of estrogen receptors. The alignment 
score for ER-α and ER-β is not very high — 44. In con-
trast to the first two clusters, both estrogen receptors 
(α and β) are downregulated in the EBV-infected cells 
and LCLs (see Fig. 1, e). No data on EBV-infected cells 
were reported yet.
Both ERs can be regulated by AhR/Arnt heterodi-
mer in the absence of ligand, which is the fascinating 
link to the role of ERs in the EBV induced transforma-
tion. Recently, we have shown that EBNA-3 could bind 
AhR and the nuclear fraction of AhR was enriched in 
the presence of EBNA-3 [81]. It is likely that EBNA-3 
family proteins may interfere with ERs. This hypothesis 
should be further elucidated.
Next cluster includes all of other receptors 
(see Fig. 1, c). All of the 16 proteins discussed here 
share common features — they possess C4 zinc finger 
of nuclear hormone receptor (smart 00399, ZnF_C4) 
and the ligand-binding domain of nuclear receptors 
(smart 00430, HOLI). All of them are homologues to 
v-ERBA with different score of alignment (highest — 
THR, score of 77; lowest — GCCR, score of 16).
THE INTERSECTION OF NUCLEAR 
RECEPTOR PATHWAYS
As we have already mentioned, we have determined 
a set of nuclear receptors that are up- (and down-) 
regulated in the latency III infected cells [10]. Some 
receptors were shown before to be implicated in the 
EBV biology, like NUR77, RXRA, RXRB, RARA, and 
GCCR. Other proteins were not connected to lym-
phoblasts — MINOR, TF COUP I and II, ER-α and -β, 
PPARG, RORC, LXRA, THRB, VDR, and GCNF. The 
important role of the regulation of the expression of 
nuclear receptors in transformation process may be 
concluded from the fact that many of them can control 
transcription of genes involved in B cell activation or 
apoptosis. For example, upregulated GCNF gene can 
activate B cell specific transcription factors Pax2/5 and 
Gbx2 that specifically induce IL-6 [17, 18]. 
We have to mention that data obtained in our study 
[10] show a correlation with the literature data. For 
instance, others [30, 33] and we [10] have shown 
that CD40 ligand downregulated PPARG, which can 
induce apoptosis in B cells. Importantly, PPARG was 
downregulated in the EBV-infected cells and LCLs 
[10]. Moreover, not only protein level was changed, but 
a cellular distribution of PPARG in the naïve, activated 
and infected cells as well. As we discussed earlier, the 
NFκB pathway becomes activated upon EBV-induced 
transformation. From the other hand, it was reported 
that PPARG binding to RelA resulted in the nuclear 
export of RelA, thus inhibiting NF-κB pathway [31]. 
Noteworthy, EBV decreased mRNA level of PPARG and 
changed the cellular distribution of PPARG [10].
It is important to notice that the ERs (both, -α 
and -β) have an ERRE in the promoter region of RARA 
gene. This makes them an important target to study in 
the process of EBV-induced transformation.
Also, we have found that there is a crosstalk be-
tween RARA and GCCR. RARA binds the Z lytic protein 
of EBV, and this binding prevents re-activation of the 
lytic cycle in the latency III cells. RXRA and RXRB bind 
Z protein too: one of them is upregulated and other 
is downregulated by EBV (see Fig. 1). Probably, EBV 
delicately regulates the levels of these receptors to 
achieve the optimal expression of the target genes 
involved in the B cell transformation.
Summarizing, we can conclude that there is a wide 
unexplored area of the role of nuclear receptors that 
might be involved in EBV-induced B cell transforma-
tion. Extensive study of cellular nuclear receptor 
pathways is needed to fully understand their role in the 
process of malignant cell transformation.
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